A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

C. Yurdaydin; R. Idilman; O. Keskin; C. Kalkan; F. M. Karakaya; A. Caliskan; E. Yurdcu; S. C. Karatayli; M. A. Bozdayi; K. Kazempour; C. Koh; T. Heller; J. S. Glenn

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

C. Yurdaydin
, R. Idilman
, O. Keskin
, C. Kalkan
, F. M. Karakaya
, A. Caliskan
, E. Yurdcu
, S. C. Karatayli
, M. A. Bozdayi
, K. Kazempour
, C. Koh
, T. Heller
, J. S. Glenn

Division of Internal Medicine (Medicine)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	10-10
Number of pages	1
Journal	Journal of Viral Hepatitis
Volume	25
Publication status	Published - Jun 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Yurdaydin, C., Idilman, R., Keskin, O., Kalkan, C., Karakaya, F. M., Caliskan, A., Yurdcu, E., Karatayli, S. C., Bozdayi, M. A., Kazempour, K., Koh, C., Heller, T., & Glenn, J. S. (2018). A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay. Journal of Viral Hepatitis, 25, 10-10.

@article{56ccf9da36ac43d9aab6e012d322678b,

title = "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene{\textregistered} real-time qPCR HDV RNA assay",

author = "C. Yurdaydin and R. Idilman and O. Keskin and C. Kalkan and Karakaya, \{F. M.\} and A. Caliskan and E. Yurdcu and Karatayli, \{S. C.\} and Bozdayi, \{M. A.\} and K. Kazempour and C. Koh and T. Heller and Glenn, \{J. S.\}",

year = "2018",

month = jun,

language = "English",

volume = "25",

pages = "10--10",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

}

Yurdaydin, C, Idilman, R, Keskin, O, Kalkan, C, Karakaya, FM, Caliskan, A, Yurdcu, E, Karatayli, SC, Bozdayi, MA, Kazempour, K, Koh, C, Heller, T & Glenn, JS 2018, 'A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay', Journal of Viral Hepatitis, vol. 25, pp. 10-10.

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay. / Yurdaydin, C.; Idilman, R.; Keskin, O. et al.
In: Journal of Viral Hepatitis, Vol. 25, 06.2018, p. 10-10.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

AU - Yurdaydin, C.

AU - Idilman, R.

AU - Keskin, O.

AU - Kalkan, C.

AU - Karakaya, F. M.

AU - Caliskan, A.

AU - Yurdcu, E.

AU - Karatayli, S. C.

AU - Bozdayi, M. A.

AU - Kazempour, K.

AU - Koh, C.

AU - Heller, T.

AU - Glenn, J. S.

PY - 2018/6

Y1 - 2018/6

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000435101000010&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 1352-0504

VL - 25

SP - 10

EP - 10

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

ER -

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene® real-time qPCR HDV RNA assay

UN SDGs

Other files and links

Cite this